[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CO4920230A1 - Derivados de sulfonil urea - Google Patents

Derivados de sulfonil urea

Info

Publication number
CO4920230A1
CO4920230A1 CO98004326A CO98004326A CO4920230A1 CO 4920230 A1 CO4920230 A1 CO 4920230A1 CO 98004326 A CO98004326 A CO 98004326A CO 98004326 A CO98004326 A CO 98004326A CO 4920230 A1 CO4920230 A1 CO 4920230A1
Authority
CO
Colombia
Prior art keywords
disease
acute
injury
sulfonil
urea
Prior art date
Application number
CO98004326A
Other languages
English (en)
Inventor
Mark Anthony Dombroski
James Frederick Eggler
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of CO4920230A1 publication Critical patent/CO4920230A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/64Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/52Y being a hetero atom
    • C07C311/54Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/52Y being a hetero atom
    • C07C311/54Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea
    • C07C311/57Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/60Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings having nitrogen atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00Sulfones; Sulfoxides
    • C07C317/14Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/64Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton
    • C07C323/67Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton containing sulfur atoms of sulfonamide groups, bound to the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/08Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/18Radicals substituted by singly bound oxygen or sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30Hetero atoms other than halogen
    • C07D333/34Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/02Systems containing only non-condensed rings with a three-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/04Systems containing only non-condensed rings with a four-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/06Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14The ring being saturated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/02Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un compuesto de la fórmula I en la que R1 y R2 son tal como sehan definido anteriormente, útil en el tratamiento y estado seleccionado entre el grupo formado por meningitis y salpingitis, choque séptico, coagulación intravascular diseminada, y/o el síndrome de distrés respiratorio en adultos, inflamación aguda o crónica, artritis, colangitis, colitis, encefalitis, endocarditis, glomerulonefritis, hepatitis, miocarditis, pancreatitis, pericarditis, lesiones por reperfusión, vasculitis, hipersensibilidad aguda y retardada, rechazo de injertos, y enfermedad del huésped frente al injerto, enfermedades auto-inmunes que incluyen la diabetes mellitus del Tipo I y la esclerosis múltiple, enfermedades periodonatas, fibrosis pulmonar intersticial, cirrosis, esclerosis sistémica, formación queloide, tumores que producen la IL-1 como un factor de crecimiento autocrino, caquexia, enfermedad de Alzheimer, lesión por percusión, depresión, ateroesclérosis y osteoporósis en un mamífero, incluyendo un humano.
CO98004326A 1997-01-29 1998-01-29 Derivados de sulfonil urea CO4920230A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3697997P 1997-01-29 1997-01-29

Publications (1)

Publication Number Publication Date
CO4920230A1 true CO4920230A1 (es) 2000-05-29

Family

ID=21891776

Family Applications (1)

Application Number Title Priority Date Filing Date
CO98004326A CO4920230A1 (es) 1997-01-29 1998-01-29 Derivados de sulfonil urea

Country Status (40)

Country Link
US (2) US6166064A (es)
EP (1) EP0964849B1 (es)
JP (1) JP3573757B2 (es)
KR (1) KR100324058B1 (es)
CN (1) CN1127479C (es)
AP (1) AP929A (es)
AR (1) AR011093A1 (es)
AT (2) ATE270285T1 (es)
AU (1) AU723895B2 (es)
BG (1) BG103597A (es)
BR (1) BR9714328A (es)
CA (1) CA2279186C (es)
CO (1) CO4920230A1 (es)
CZ (1) CZ293173B6 (es)
DE (2) DE69722663T2 (es)
DK (2) DK1270565T3 (es)
DZ (1) DZ2407A1 (es)
EA (1) EA001803B1 (es)
ES (2) ES2198598T3 (es)
HR (1) HRP980045B1 (es)
HU (1) HUP0000567A3 (es)
ID (1) ID22223A (es)
IL (1) IL130855A0 (es)
IS (1) IS5099A (es)
MA (1) MA26468A1 (es)
NO (1) NO313279B1 (es)
NZ (1) NZ336248A (es)
OA (1) OA11079A (es)
PA (1) PA8444701A1 (es)
PE (1) PE57898A1 (es)
PL (1) PL335052A1 (es)
PT (2) PT964849E (es)
SK (1) SK283679B6 (es)
TN (1) TNSN98017A1 (es)
TR (1) TR199901816T2 (es)
TW (1) TW515788B (es)
UY (1) UY24861A1 (es)
WO (1) WO1998032733A1 (es)
YU (1) YU33799A (es)
ZA (1) ZA98685B (es)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6022984A (en) * 1998-07-27 2000-02-08 Pfizer Inc. Efficient synthesis of furan sulfonamide compounds useful in the synthesis of new IL-1 inhibitors
EP1526383A3 (en) * 1998-08-31 2005-11-16 Pfizer Products Inc. Diarylsulfonylurea binding proteins
IT1303249B1 (it) * 1998-10-23 2000-11-06 Dompe Spa Alcune n-(2-aril-propionil)-solfonammidi e preparazionifarmaceutiche che le contengono.
AU6464400A (en) * 1999-09-14 2001-04-17 Pfizer Products Inc. Combination treatment with il-1ra and diaryl sulphonyl urea compounds
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
CA2369967A1 (en) * 2001-02-12 2002-08-12 Joseph Anthony Cornicelli Methods of treating nuclear factor-kappa b mediated diseases and disorders
CN1547486A (zh) 2001-06-26 2004-11-17 抗opgl抗体
CA2459454A1 (en) 2001-09-14 2003-03-27 Bayer Pharmaceuticals Corporation Benzofuran and dihydrobenzofuran derivatives useful as beta-3 adrenoreceptor agonists
MXPA04002565A (es) * 2001-11-30 2004-05-31 Pfizer Prod Inc Combinacion de un inhibidor de il-1/18 con un inhibidor de tnf para el tratamiento de inflamacion.
US20030131370A1 (en) * 2001-12-14 2003-07-10 Pfizer Inc. Disruption of the glutathione S-transferase-Omega-1 gene
AU2003245989A1 (en) 2002-07-09 2004-01-23 Boehringer Ingelheim Pharma Gmbh And Co. Kg Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases
AR041173A1 (es) 2002-09-06 2005-05-04 Amgen Inc Aniticuerpo monoclonal anti- il- 1r1 humano terapeutico
AU2003263560A1 (en) * 2002-10-03 2004-04-23 Pfizer Products Inc. Use of gst-omega-2 as a therapeutic target
CL2004002015A1 (es) 2003-08-06 2005-05-13 Senomyx Inc Derivados de amida, productos que las contienen, utiles para modificar el sabor de alimentos y medicamentos.
ATE444286T1 (de) * 2004-03-23 2009-10-15 Dompe Pha R Ma Spa Res & Mfg 2-phenylpropionsäurederivate und diese enthaltende pharmazeutische zusammensetzung
US20060045953A1 (en) * 2004-08-06 2006-03-02 Catherine Tachdjian Aromatic amides and ureas and their uses as sweet and/or umami flavor modifiers, tastants and taste enhancers
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
WO2006084186A2 (en) 2005-02-04 2006-08-10 Senomyx, Inc. Compounds comprising linked hetero aryl moieties and their use as novel umami flavor modifiers, tastants and taste enhancers for comestible compositions
WO2006090932A1 (ja) * 2005-02-28 2006-08-31 Eisai R & D Managemant Co., Ltd. スルホンアミド化合物の代理マーカー
US7208526B2 (en) * 2005-05-20 2007-04-24 Hoffmann-La Roche Inc. Styrylsulfonamides
TW200715993A (en) 2005-06-15 2007-05-01 Senomyx Inc Bis-aromatic amides and their uses as sweet flavor modifiers, tastants, and taste enhancers
KR101387563B1 (ko) 2006-04-21 2014-04-25 세노믹스, 인코포레이티드 고효능의 조미용 향료를 포함하는 식품 조성물 및 이의 제조 방법
EP1992344A1 (en) 2007-05-18 2008-11-19 Institut Curie P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
US7973051B2 (en) * 2007-11-30 2011-07-05 Hoffman-La Roche Inc. Aminothiazoles as FBPase inhibitors for diabetes
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
US10385040B2 (en) 2014-08-12 2019-08-20 Loyola University Of Chicago Indoline sulfonamide inhibitors of DapE and NDM-1 and use of the same
AU2016222278B2 (en) 2015-02-16 2020-07-09 The Provost, Fellows, Foundation Scholars, And The Other Members Of Board, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Sulfonylureas and related compounds and use of same
WO2016138473A1 (en) * 2015-02-26 2016-09-01 H. Lee Moffitt Cancer Center And Research Institute, Inc. Inflammasome activation in myelodysplastic syndromes
FR3046933B1 (fr) 2016-01-25 2018-03-02 Galderma Research & Development Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires
EP3416948B1 (en) * 2016-02-16 2024-07-24 The University Of Queensland Indacene bearing sulfonylureas as anti-inflammatory agents
EP3445757B1 (en) * 2016-04-18 2020-11-25 Novartis Inflammasome Research, Inc. Compounds and compositions for treating conditions associated with nlrp activity
EP3445749B1 (en) * 2016-04-18 2022-12-21 Novartis AG Compounds and compositions for treating conditions associated with nlrp activity
EP3272739A1 (en) * 2016-07-20 2018-01-24 NodThera Limited Sulfonyl urea derivatives and their use in the control of interleukin-1 activity
AU2017367086A1 (en) * 2016-11-29 2019-07-18 Epizyme, Inc. Compounds containing a sulfonic group as KAT inhibitors
CN110366549A (zh) 2017-01-23 2019-10-22 基因泰克公司 作为白介素-1活性抑制剂的化合物
US11840543B2 (en) 2017-05-24 2023-12-12 The University Of Queensland Compounds and uses
EP3634951B8 (en) 2017-06-09 2024-08-21 Zydus Lifesciences Limited Novel substituted sulfoximine compounds
EP3649112A1 (en) 2017-07-07 2020-05-13 Inflazome Limited Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors
IL271716B2 (en) 2017-07-07 2024-09-01 Inflazome Ltd Sulfonamide Carboxamide Compounds as NLRP3 Inhibitors, Pharmaceutical Preparations and Their Uses
PT3658539T (pt) 2017-07-24 2024-04-26 Novartis Ag Compostos e composições para tratar condições associadas à atividade de nlrp
EP3668843A1 (en) 2017-08-15 2020-06-24 Inflazome Limited Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors
US11613542B2 (en) 2017-08-15 2023-03-28 Inflazome Limited Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors
US11518739B2 (en) 2017-08-15 2022-12-06 Inflazome Limited Sulfonamide carboxamide compounds
BR112020002906A2 (pt) 2017-08-15 2020-08-04 Inflazome Limited novos compostos de sulfonamida-carboxamida
EP3668842A1 (en) 2017-08-15 2020-06-24 Inflazome Limited Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors
WO2019043610A1 (en) 2017-08-31 2019-03-07 Cadila Healthcare Limited NEW SUBSTITUTED SULFONYLUREA DERIVATIVES
WO2019068772A1 (en) 2017-10-03 2019-04-11 Inflazome Limited NEW COMPOUNDS
WO2019079119A1 (en) 2017-10-17 2019-04-25 IFM Tre, Inc. SULFONAMIDES AND ASSOCIATED COMPOSITIONS FOR THE TREATMENT OF PATHOLOGICAL CONDITIONS ASSOCIATED WITH NLRP ACTIVITY
MX2020004423A (es) 2017-11-09 2020-08-06 Inflazome Ltd Nuevos compuestos de sulfonamida carboxamida.
GB201721185D0 (en) * 2017-12-18 2018-01-31 Nodthera Ltd Sulphonyl urea derivatives
CN108299256B (zh) * 2018-01-09 2019-09-10 武汉大学 一类2,3,4-三羟基苯磺酰胺衍生物及其制备方法和应用
EP3759090A1 (en) 2018-03-02 2021-01-06 Inflazome Limited Novel compounds
WO2019166619A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
WO2019166632A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
US11884645B2 (en) 2018-03-02 2024-01-30 Inflazome Limited Sulfonyl acetamides as NLRP3 inhibitors
EP3759102A1 (en) 2018-03-02 2021-01-06 Inflazome Limited Novel compounds
JP2021529187A (ja) * 2018-07-03 2021-10-28 ノバルティス アーゲー Nlrpモジュレータ
CR20210024A (es) * 2018-07-20 2021-02-22 Hoffmann La Roche Compuestos de sulfonilurea como inhibidores de la actividad de interleucina 1
WO2020035482A1 (en) 2018-08-13 2020-02-20 Iltoo Pharma Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
CN113056451A (zh) 2018-10-24 2021-06-29 诺华股份有限公司 用于治疗与nlrp活性相关的病症的化合物和组合物
SG11202107680PA (en) 2019-01-14 2021-08-30 Cadila Healthcare Ltd Novel substituted sulfonylurea derivatives
FI3983387T3 (fi) 2019-06-12 2024-07-09 Nodthera Ltd Sulfonyyliureajohdannaisia ja niiden käyttötarkoituksia
WO2020254697A1 (en) 2019-06-21 2020-12-24 Ac Immune Sa Fused 1,2 thiazoles and 1,2 thiazines which act as nl3p3 modulators
US20220313657A1 (en) * 2019-09-12 2022-10-06 Cadila Healthcare Limited Novel substituted sulfoximine derivatives
EP4166541A4 (en) * 2020-06-11 2024-09-04 Cisen Pharmaceutical Co Ltd DIMETHYLSULFOXIMINE DERIVATIVE
CA3178361A1 (en) 2020-06-19 2021-12-23 Emanuele Gabellieri Dihydrooxazole and thiourea derivatives modulating the nlrp3 inflammasome pathway
WO2022022646A1 (zh) * 2020-07-29 2022-02-03 南京明德新药研发有限公司 含硒五元杂芳环化合物
JP2023540733A (ja) 2020-09-04 2023-09-26 ノッドセラ リミテッド アルキルオキサシクロアルキル部分を含むスルファモイル尿素誘導体およびその使用
ES2948511A1 (es) * 2021-09-08 2023-09-13 Fundacion Para La Investigacion Biomedica Del Hospital Univ De La Princesa Derivados de n-sulfonilureas y su uso terapeutico
WO2023098612A1 (zh) * 2021-12-03 2023-06-08 南京明德新药研发有限公司 二甲基亚磺酰亚胺衍生物的盐型及晶型
EP4452972A1 (en) 2021-12-22 2024-10-30 AC Immune SA Dihydro-oxazol derivative compounds
AR128498A1 (es) * 2022-02-15 2024-05-15 Hoffmann La Roche Procesos novedosos
WO2023222565A1 (en) 2022-05-16 2023-11-23 Institut National de la Santé et de la Recherche Médicale Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation
US20240034735A1 (en) 2022-07-14 2024-02-01 Ac Immune Sa Novel compounds
WO2024023266A1 (en) 2022-07-28 2024-02-01 Ac Immune Sa Novel compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4586950A (en) * 1982-05-31 1986-05-06 E. I. Du Pont De Nemours & Company Novel phenyl-substituted sulfonamides
US4780125A (en) * 1982-09-01 1988-10-25 Ciba-Geigy Corporation N-phenylsulfonyl-N'-triazinylureas
DE3927369A1 (de) * 1989-08-19 1991-02-21 Bayer Ag Substituierte n-(chinolin-2-yl-methoxy)benzyl-sulfonyl-harnstoffe
US5064851A (en) * 1990-07-24 1991-11-12 Pfizer Inc. 3-(1-substituted-pyrazoyl)-2-oxindole derivatives, compositions and use
US5254589A (en) * 1991-10-15 1993-10-19 Warner-Lambert Company Sulfonyl urea and carbamate ACAT inhibitors
DE4344957A1 (de) * 1993-12-30 1995-07-06 Hoechst Ag Substituierte Benzolsulfonylharnstoffe und -thioharnstoffe, Herstellungsverfahren und Verwendungsmöglichkeiten pharmazeutischer Präparate auf Basis dieser Verbindungen
CN1038679C (zh) * 1994-12-07 1998-06-10 南开大学 磺酰脲类化合物及其除草用途
HU226462B1 (en) * 1995-02-17 2008-12-29 Hoechst Ag Substituted benzol-sulfonyl-ureas and -thioureas, process for producing them, pharmaceutical compositions containing them, and their use
AU6967198A (en) * 1997-04-10 1998-10-30 Eli Lilly And Company Diarylsulfonylureas for use in treating secretory diarrhea

Also Published As

Publication number Publication date
NO993658L (no) 1999-09-28
ATE242208T1 (de) 2003-06-15
HUP0000567A2 (hu) 2000-10-28
ATE270285T1 (de) 2004-07-15
DE69722663T2 (de) 2004-04-29
PT1270565E (pt) 2004-09-30
HRP980045B1 (en) 2002-10-31
OA11079A (en) 2002-03-14
ES2222426T3 (es) 2005-02-01
JP2000511200A (ja) 2000-08-29
NZ336248A (en) 2000-10-27
SK283679B6 (sk) 2003-11-04
IL130855A0 (en) 2001-01-28
ZA98685B (en) 1999-07-29
KR100324058B1 (ko) 2002-02-16
EP0964849A1 (en) 1999-12-22
DK0964849T3 (da) 2003-08-25
UY24861A1 (es) 2000-09-29
SK98299A3 (en) 2001-10-08
AR011093A1 (es) 2000-08-02
PL335052A1 (en) 2000-03-27
ES2198598T3 (es) 2004-02-01
DE69729762D1 (de) 2004-08-05
CZ293173B6 (cs) 2004-02-18
TW515788B (en) 2003-01-01
WO1998032733A1 (en) 1998-07-30
HUP0000567A3 (en) 2002-10-28
CN1127479C (zh) 2003-11-12
US6166064A (en) 2000-12-26
DE69729762T2 (de) 2005-07-14
PA8444701A1 (es) 2000-05-24
BR9714328A (pt) 2000-03-21
CA2279186A1 (en) 1998-07-30
EA001803B1 (ru) 2001-08-27
JP3573757B2 (ja) 2004-10-06
AP9801190A0 (en) 1998-03-31
TR199901816T2 (xx) 1999-11-22
MA26468A1 (fr) 2004-12-20
DE69722663D1 (de) 2003-07-10
EA199900603A1 (ru) 2000-02-28
CN1245490A (zh) 2000-02-23
CA2279186C (en) 2004-02-24
AU5234098A (en) 1998-08-18
EP0964849B1 (en) 2003-06-04
US6433009B1 (en) 2002-08-13
AP929A (en) 2001-01-18
DK1270565T3 (da) 2004-10-04
NO313279B1 (no) 2002-09-09
AU723895B2 (en) 2000-09-07
CZ257599A3 (cs) 2000-09-13
DZ2407A1 (fr) 2003-01-04
ID22223A (id) 1999-09-16
IS5099A (is) 1999-06-29
HRP980045A2 (en) 1999-06-30
NO993658D0 (no) 1999-07-28
TNSN98017A1 (fr) 2005-03-15
BG103597A (bg) 2000-02-29
KR20000070541A (ko) 2000-11-25
PT964849E (pt) 2003-08-29
PE57898A1 (es) 1999-06-11
YU33799A (sh) 2002-03-18

Similar Documents

Publication Publication Date Title
CO4920230A1 (es) Derivados de sulfonil urea
RU99105213A (ru) Применение хелатирующего агента клиохинола для производства фармацевтической композиции для лечения болезни альцгеймера
DE50008635D1 (de) Brausekopf für eine sanitäre Brause
Balon et al. Fishes of the Tatinga River, Comoros, with comments on freshwater amphidromy in the goby Sicyopterus lagocephalus
ECSP982371A (es) Derivados de sulfonil urea
ES2191850T3 (es) Dispositivo para la limpieza de la cavidad bucal.
Coldstream The Cesnola painter: a change of address
CY1107756T1 (el) Αναλογα θειου της 21-υδροξυ-6, 19-οξειδοπρογεστερονης (21oh-6οp) για τη θεραπεια πλεονασματος γλυκοκορτικοειδων
DE50105102D1 (de) Matratze und Verfahren zur Herstellung derselben
Theeler et al. The larva of Apomyrma (Hymenoptera: Formicidae)
USD203039S (en) Stroller
Parpinelli Being as Beauty. Lines of an Art Theory in Antonio Rosmini
USD156103S (en) Design for a glove
JPS53112972A (en) Surface treatment of allyl resin molded article
USD232125S (en) Character print member
USD156007S (en) Design for a glove
USD160831S (en) Child s hooded suit
Watling et al. Two new cumacean (Crustacea) species from the deep South Atlantic
Manhire Our father; Early days in the colony
USD159815S (en) Negligee coat
USD156442S (en) Child s cap
USD232391S (en) Accessory hairpiece
USD193175S (en) Handle for a brush or the like
Ruggerone et al. Chignik Lakes Research: Investigations of Salmon Populations, Hydrology, and Limnology of the Chignik Lakes, Alaska During 2000
Guada LUTTERWORTH CURFEW BELL.